Tags

Type your tag names separated by a space and hit enter

Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Oncol Rep. 2011 Apr; 25(4):1131-8.OR

Abstract

It has been suggested that expression of TGFβ1 and its receptors [TGFβ receptor type I (TβRI) and TGFβ receptor type II (TβRII)] may play a key role in the proliferation and progression of epithelial ovarian cancer. We investigated the biological significance of TGFβ1 and its receptors, as well as their association with the tumor response to paclitaxel (PTX) and carboplatin (CBDCA). We studied 24 patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who had undergone surgery and chemotherapy with PTX and CBDCA. Tissues from the primary tumor were examined and the expression of TGFβ1, TβRI, and TβRII mRNA was assessed by the RNase protection assay. It was found that TGFβ1 mRNA expression was significantly lower in the tumors of patients who had optimal surgery than in the tumors of patients with suboptimal surgery. TGFβ1 mRNA expression was also significantly lower in tumors with high sensitivity to PTX and CBDCA than in those with low sensitivity. TβRI mRNA expression was not associated with any clinicopathological factors. Expression of TβRII mRNA was significantly higher in clear cell adenocarcinoma and mucinous adenocarcinoma, while it was lower in serous adenocarcinoma and endometrioid adenocarcinoma. Moreover, it tended to be higher in early-stage tumors compared with advanced tumors. Among TGFβ1, TβRI, and TβRII, expression of TGFβ1 mRNA was most strongly associated with progression-free survival. When the prognosis of the patients with advanced cancer was compared on the basis of TGFβ1 mRNA expression, those whose tumors showed low expression tended to have a better prognosis than those whose tumors showed high expression. It is suggested that TGFβ1 mRNA expression is an indicator of tumor sensitivity to standard therapy with PTX and CBDCA, that it can identify biologically aggressive and highly malignant tumors and that it can predict the prognosis of patients with ovarian cancer.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan. shinkomiyama@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21249319

Citation

Komiyama, Shinichi, et al. "Expression of TGFβ1 and Its Receptors Is Associated With Biological Features of Ovarian Cancer and Sensitivity to Paclitaxel/carboplatin." Oncology Reports, vol. 25, no. 4, 2011, pp. 1131-8.
Komiyama S, Kurahashi T, Ishikawa M, et al. Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin. Oncol Rep. 2011;25(4):1131-8.
Komiyama, S., Kurahashi, T., Ishikawa, M., Tanaka, K., Komiyama, M., Mikami, M., & Udagawa, Y. (2011). Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin. Oncology Reports, 25(4), 1131-8. https://doi.org/10.3892/or.2011.1151
Komiyama S, et al. Expression of TGFβ1 and Its Receptors Is Associated With Biological Features of Ovarian Cancer and Sensitivity to Paclitaxel/carboplatin. Oncol Rep. 2011;25(4):1131-8. PubMed PMID: 21249319.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin. AU - Komiyama,Shinichi, AU - Kurahashi,Takashi, AU - Ishikawa,Mitsuya, AU - Tanaka,Kyoko, AU - Komiyama,Mizuka, AU - Mikami,Mikio, AU - Udagawa,Yasuhiro, Y1 - 2011/01/18/ PY - 2010/09/16/received PY - 2010/12/02/accepted PY - 2011/1/21/entrez PY - 2011/1/21/pubmed PY - 2011/7/16/medline SP - 1131 EP - 8 JF - Oncology reports JO - Oncol Rep VL - 25 IS - 4 N2 - It has been suggested that expression of TGFβ1 and its receptors [TGFβ receptor type I (TβRI) and TGFβ receptor type II (TβRII)] may play a key role in the proliferation and progression of epithelial ovarian cancer. We investigated the biological significance of TGFβ1 and its receptors, as well as their association with the tumor response to paclitaxel (PTX) and carboplatin (CBDCA). We studied 24 patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who had undergone surgery and chemotherapy with PTX and CBDCA. Tissues from the primary tumor were examined and the expression of TGFβ1, TβRI, and TβRII mRNA was assessed by the RNase protection assay. It was found that TGFβ1 mRNA expression was significantly lower in the tumors of patients who had optimal surgery than in the tumors of patients with suboptimal surgery. TGFβ1 mRNA expression was also significantly lower in tumors with high sensitivity to PTX and CBDCA than in those with low sensitivity. TβRI mRNA expression was not associated with any clinicopathological factors. Expression of TβRII mRNA was significantly higher in clear cell adenocarcinoma and mucinous adenocarcinoma, while it was lower in serous adenocarcinoma and endometrioid adenocarcinoma. Moreover, it tended to be higher in early-stage tumors compared with advanced tumors. Among TGFβ1, TβRI, and TβRII, expression of TGFβ1 mRNA was most strongly associated with progression-free survival. When the prognosis of the patients with advanced cancer was compared on the basis of TGFβ1 mRNA expression, those whose tumors showed low expression tended to have a better prognosis than those whose tumors showed high expression. It is suggested that TGFβ1 mRNA expression is an indicator of tumor sensitivity to standard therapy with PTX and CBDCA, that it can identify biologically aggressive and highly malignant tumors and that it can predict the prognosis of patients with ovarian cancer. SN - 1791-2431 UR - https://www.unboundmedicine.com/medline/citation/21249319/Expression_of_TGFβ1_and_its_receptors_is_associated_with_biological_features_of_ovarian_cancer_and_sensitivity_to_paclitaxel/carboplatin_ L2 - http://www.spandidos-publications.com/or/25/4/1131 DB - PRIME DP - Unbound Medicine ER -